Tandem Diabetes Care Stock Z Score

TNDM Stock

USD 33.47 0.86 2.64%

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Tandem Diabetes Piotroski F Score and Tandem Diabetes Valuation analysis.

At this time, Tandem Diabetes' Capital Expenditures is very stable compared to the past year. As of the 16th of February 2025, Long Term Debt To Capitalization is likely to grow to 0.46, while Capital Surpluse is likely to drop about 776.1 M. At this time, Tandem Diabetes' Income Tax Expense is very stable compared to the past year. As of the 16th of February 2025, Total Revenue is likely to grow to about 902.9 M, though Operating Income is likely to grow to (199.4 M).

Tandem Diabetes Care Company Z Score Analysis

Tandem Diabetes' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Z Score

Sum Of

5 Factors

More About Z Score | All Equity Analysis

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Tandem Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Tandem Diabetes is extremely important. It helps to project a fair market value of Tandem Stock properly, considering its historical fundamentals such as Z Score. Since Tandem Diabetes' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tandem Diabetes' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tandem Diabetes' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Intangible Assets	Long Term Debt	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.94	0.93	-0.87	0.87	0.99	0.98	0.97	1.0	-0.11	0.79	0.98	0.83	0.5	0.94	0.98	0.94	0.9	0.6	0.61	0.95	0.95	0.91
Total Stockholder Equity	0.94		0.76	-0.85	0.76	0.94	0.95	0.82	0.96	-0.18	0.89	0.9	0.64	0.56	0.9	0.93	0.9	0.9	0.58	0.63	0.93	0.94	0.78
Net Debt	0.93	0.76		-0.8	0.86	0.91	0.89	0.98	0.9	0.06	0.6	0.94	0.93	0.38	0.85	0.9	0.85	0.78	0.56	0.54	0.85	0.84	0.93
Retained Earnings	-0.87	-0.85	-0.8		-0.89	-0.9	-0.83	-0.82	-0.86	-0.06	-0.89	-0.91	-0.76	-0.23	-0.93	-0.83	-0.93	-0.91	-0.78	-0.84	-0.81	-0.81	-0.78
Accounts Payable	0.87	0.76	0.86	-0.89		0.87	0.78	0.87	0.84	0.1	0.74	0.9	0.86	0.1	0.89	0.81	0.88	0.79	0.65	0.66	0.75	0.75	0.82
Net Receivables	0.99	0.94	0.91	-0.9	0.87		0.98	0.95	0.99	-0.09	0.82	0.98	0.81	0.48	0.97	0.98	0.97	0.92	0.67	0.67	0.96	0.96	0.9
Short Term Investments	0.98	0.95	0.89	-0.83	0.78	0.98		0.92	0.99	-0.15	0.79	0.94	0.74	0.62	0.92	0.98	0.92	0.9	0.58	0.6	0.97	0.98	0.87
Total Liab	0.97	0.82	0.98	-0.82	0.87	0.95	0.92		0.95	-0.05	0.66	0.97	0.91	0.41	0.9	0.95	0.89	0.83	0.56	0.55	0.9	0.89	0.94
Total Current Assets	1.0	0.96	0.9	-0.86	0.84	0.99	0.99	0.95		-0.13	0.81	0.97	0.79	0.55	0.94	0.98	0.94	0.91	0.59	0.62	0.97	0.97	0.89
Short Term Debt	-0.11	-0.18	0.06	-0.06	0.1	-0.09	-0.15	-0.05	-0.13		-0.16	-0.02	-0.03	-0.18	-0.13	-0.26	-0.13	-0.17	0.15	0.3	-0.16	-0.17	-0.11
Common Stock	0.79	0.89	0.6	-0.89	0.74	0.82	0.79	0.66	0.81	-0.16		0.78	0.55	0.33	0.86	0.79	0.86	0.92	0.62	0.78	0.82	0.82	0.7
Property Plant Equipment	0.98	0.9	0.94	-0.91	0.9	0.98	0.94	0.97	0.97	-0.02	0.78		0.88	0.4	0.94	0.96	0.94	0.89	0.64	0.65	0.91	0.91	0.92
Current Deferred Revenue	0.83	0.64	0.93	-0.76	0.86	0.81	0.74	0.91	0.79	-0.03	0.55	0.88		0.11	0.8	0.82	0.79	0.68	0.47	0.44	0.68	0.67	0.9
Intangible Assets	0.5	0.56	0.38	-0.23	0.1	0.48	0.62	0.41	0.55	-0.18	0.33	0.4	0.11		0.34	0.53	0.34	0.44	0.15	0.17	0.63	0.64	0.34
Long Term Debt	0.94	0.9	0.85	-0.93	0.89	0.97	0.92	0.9	0.94	-0.13	0.86	0.94	0.8	0.34		0.94	1.0	0.92	0.71	0.76	0.89	0.89	0.85
Net Tangible Assets	0.98	0.93	0.9	-0.83	0.81	0.98	0.98	0.95	0.98	-0.26	0.79	0.96	0.82	0.53	0.94		0.94	0.9	0.55	0.55	0.95	0.95	0.9
Long Term Debt Total	0.94	0.9	0.85	-0.93	0.88	0.97	0.92	0.89	0.94	-0.13	0.86	0.94	0.79	0.34	1.0	0.94		0.92	0.71	0.76	0.89	0.89	0.85
Capital Surpluse	0.9	0.9	0.78	-0.91	0.79	0.92	0.9	0.83	0.91	-0.17	0.92	0.89	0.68	0.44	0.92	0.9	0.92		0.73	0.79	0.94	0.94	0.84
Deferred Long Term Liab	0.6	0.58	0.56	-0.78	0.65	0.67	0.58	0.56	0.59	0.15	0.62	0.64	0.47	0.15	0.71	0.55	0.71	0.73		0.81	0.6	0.61	0.58
Short Long Term Debt	0.61	0.63	0.54	-0.84	0.66	0.67	0.6	0.55	0.62	0.3	0.78	0.65	0.44	0.17	0.76	0.55	0.76	0.79	0.81		0.64	0.65	0.55
Net Invested Capital	0.95	0.93	0.85	-0.81	0.75	0.96	0.97	0.9	0.97	-0.16	0.82	0.91	0.68	0.63	0.89	0.95	0.89	0.94	0.6	0.64		1.0	0.85
Net Working Capital	0.95	0.94	0.84	-0.81	0.75	0.96	0.98	0.89	0.97	-0.17	0.82	0.91	0.67	0.64	0.89	0.95	0.89	0.94	0.61	0.65	1.0		0.85
Capital Stock	0.91	0.78	0.93	-0.78	0.82	0.9	0.87	0.94	0.89	-0.11	0.7	0.92	0.9	0.34	0.85	0.9	0.85	0.84	0.58	0.55	0.85	0.85

Click cells to compare fundamentals

To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.

Competition

Predict Tandem Diabetes

Based on the company's disclosures, Tandem Diabetes Care has a Z Score of 0.0. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.

Tandem Diabetes ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tandem Diabetes' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tandem Diabetes' managers, analysts, and investors.

Environmental

Governance

Social

Tandem Diabetes Institutional Holders

Institutional Holdings refers to the ownership stake in Tandem Diabetes that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Tandem Diabetes' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Tandem Diabetes' value.

		Shares
Jennison Associates Llc	2024-12-31	1.5 M
Millennium Management Llc	2024-09-30	1.4 M
Park West Asset Management Llc	2024-09-30	1.1 M
Divisadero Street Capital Management, Lp	2024-09-30	1.1 M
First Light Asset Management, Llc	2024-09-30	1 M
Morgan Stanley - Brokerage Accounts	2024-09-30	992.7 K
Next Century Growth Investors Llc	2024-09-30	982.7 K
Chicago Capital, Llc	2024-12-31	970.6 K
Hhg Plc	2024-09-30	913.5 K
Blackrock Inc	2024-09-30	11.1 M
Vanguard Group Inc	2024-09-30	7.4 M

Tandem Fundamentals

	Return On Equity	-0.46
	Return On Asset	-0.0969
	Profit Margin	(0.15) %
	Operating Margin	(0.11) %
	Current Valuation	2.2 B
	Shares Outstanding	65.68 M
	Shares Owned By Insiders	1.04 %
	Shares Owned By Institutions	98.96 %
	Number Of Shares Shorted	6.93 M
	Price To Earning	494.25 X
	Price To Book	9.25 X
	Price To Sales	2.57 X
	Revenue	747.72 M
	Gross Profit	425.41 M
	EBITDA	(194.66 M)
	Net Income	(222.61 M)
	Cash And Equivalents	608.73 M
	Cash Per Share	9.47 X
	Total Debt	415.67 M
	Debt To Equity	1.00 %
	Current Ratio	4.80 X
	Book Value Per Share	3.62 X
	Cash Flow From Operations	(31.81 M)
	Short Ratio	7.36 X
	Earnings Per Share	(1.94) X
	Target Price	51.1
	Number Of Employees	2.4 K
	Beta	1.32
	Market Capitalization	2.2 B
	Total Asset	952.66 M
	Retained Earnings	(951.8 M)
	Working Capital	552.73 M
	Current Asset	106.98 M
	Current Liabilities	26.52 M
	Net Asset	952.66 M

About Tandem Diabetes Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Tandem Diabetes Care's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tandem Diabetes using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tandem Diabetes Care based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:

How To Invest In Tandem

Details

Is Tandem Stock a good investment?

Details

What is Tandem Diabetes' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Tandem Diabetes Piotroski F Score and Tandem Diabetes Valuation analysis.

You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.37)

Earnings Share

(1.94)

Revenue Per Share

13.082

Quarterly Revenue Growth

0.314

Return On Assets

(0.1)

The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tandem Diabetes Care Stock Z Score

Tandem Diabetes Care Company Z Score Analysis

Z Score

Sum Of

5 Factors

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Tandem Z Score Driver Correlations

Tandem Diabetes ESG Sustainability

Tandem Diabetes Institutional Holders

Tandem Fundamentals

About Tandem Diabetes Fundamental Analysis

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY